Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00761722 · ClinicalTrials.gov registry record · Phase 1
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00761722 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 31 participants.
The verdict
NCT00761722, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the amount of drug that gets into the bloodstream between different tablets taken by mouth and an injection under the skin.
Interventions
- DRUG azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-08-12 |
| Est. Completion | 2016-04-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00761722
The ClinicalTrials.gov registry entry for NCT00761722 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which azacitidine is the first listed.
NCT00761722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00761722 about?
NCT00761722 is a clinical study titled "Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma". The purpose of this study is to compare the amount of drug that gets into the bloodstream between different tablets taken by mouth and an injection under the skin.
What is the current status of trial NCT00761722?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2008-08-12. Estimated completion is 2016-04-07.
What interventions are being tested in trial NCT00761722?
The interventions under investigation include: azacitidine (DRUG).
Who is sponsoring clinical trial NCT00761722?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.